Clinical Trials

Carcinoma, Carcinoma, Renal Cell

NCT03142334 2026-03-10

KEYNOTE-564

994 enrolled 10 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT07000149 2026-03-10

eVOLVE-RCC02

1,116 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT02811861 2026-02-23

CLEAR

1,069 enrolled 12 charts 1 FDA

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT07405164 2026-02-12

MK-6482-043

450 enrolled

Carcinoma, Renal Cell, von Hippel-Lindau Disease

NCT02853331 2026-02-02

KEYNOTE-426

861 enrolled 24 charts 1 FDA

Carcinoma, Renal Cell

NCT03091192 2026-01-23

Savolitinib vs. Sunitinib in MET-driven PRCC.

60 enrolled 15 charts

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT03815643 2025-12-04

Avelumab Program Rollover Study

GenitourinaryGynecologicThoracic

205 enrolled

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Ovarian Neoplasms

NCT05899049 2025-11-10

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

249 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT04810078 2025-10-09

CheckMate-67T

681 enrolled 1 FDA

Phase 3 Not yet recruiting

Carcinoma, Renal Cell

NCT07197580 2025-09-29

LUTEON

40 enrolled

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT03937219 2025-09-10

COSMIC-313

855 enrolled 12 charts

Carcinoma, Carcinoma, Renal Cell, Neoplasms

NCT04987203 2025-08-22

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

343 enrolled

Carcinoma, Renal Cell, Disease Progression

NCT05239728 2025-08-14

MK-6482-022

1,800 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02684006 2025-07-30

JAVELIN Renal 101

886 enrolled 37 charts 1 FDA

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03260894 2025-07-29

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

129 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT02231749 2025-06-26

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

1,390 enrolled 18 charts 1 FDA

Carcinoma, Renal Cell

NCT03141177 2025-06-06

CheckMate 9ER

701 enrolled 17 charts 1 FDA

Carcinoma, Renal Cell

NCT05043090 2025-05-08

SAMETA

148 enrolled

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

NCT04195750 2025-04-29

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

755 enrolled 28 charts 1 FDA

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03592472 2025-04-13

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV)

Phase 3 Recruiting

413 enrolled

Carcinoma, Renal Cell

NCT00720941 2025-03-30

COMPARZ

1,110 enrolled 27 charts

Carcinoma, Renal Cell

NCT06750419 2024-12-27

89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study

Phase 3 Recruiting

82 enrolled

Carcinoma, Renal Cell

NCT03138512 2024-12-18

CheckMate 914

1,641 enrolled 21 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

NCT04736706 2024-11-18

MK-6482-012

1,653 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

NCT03849118 2024-05-17

89ZR-TLX250

300 enrolled 10 charts

Carcinoma, Renal Cell

NCT03024996 2023-08-03

IMmotion010

Phase 3 Terminated

778 enrolled 19 charts

Carcinoma, Renal Cell

NCT02627963 2023-07-18

A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)

350 enrolled 14 charts 1 FDA

Carcinoma, Renal Cell

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Phase 3 Terminated

623 enrolled 14 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT02420821 2023-01-30

IMmotion151

915 enrolled 40 charts

Carcinoma, Renal Cell

NCT01668784 2022-08-09

Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

821 enrolled 18 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01865747 2021-04-27

METEOR

658 enrolled 15 charts

Carcinoma, Renal Cell

NCT01235962 2020-11-23

PROTECT

1,538 enrolled 27 charts

Carcinoma, Renal Cell, Neoplasms

NCT00397345 2020-10-19

TroVax Renal Immunotherapy Survival Trial

733 enrolled

Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms

NCT01599754 2019-09-20

ATLAS

Phase 3 Terminated

724 enrolled 17 charts

Carcinoma, Renal Cell

NCT00087022 2018-11-27

ARISER

864 enrolled 10 charts

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03693573 2018-11-15

A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma

Phase 3 Withdrawn

Carcinoma, Renal Cell

NCT00606632 2018-10-02

Pre-surgical Detection of Clear Cell Renal Cell Carcinoma (ccRCC) Using Radiolabeled G250-Antibody

226 enrolled 10 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasms

NCT01762592 2017-12-22

REDECT 2: REnal Masses: Pivotal Trial to DEteCT Clear Cell Renal Cell Carcinoma With PET/CT

Phase 3 Withdrawn

Carcinoma, Renal Cell, Kidney Neoplasms

NCT01265901 2017-10-12

IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

339 enrolled

Carcinoma, Renal Cell

NCT01064310 2017-04-17

PISCES

169 enrolled 16 charts

Carcinoma, Renal Cell, Neoplasms, Patient Preference

NCT00061178 2016-10-19

Efficacy and Safety Study of rhuMAb VEGF to Treat Metastatic Renal Cell Carcinoma

Phase 3 Withdrawn

Carcinoma, Renal Cell

NCT00738530 2016-06-23

A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy

649 enrolled 18 charts

Carcinoma, Renal Cell

NCT00631371 2016-04-27

INTORACT

791 enrolled 11 charts

Carcinoma, Renal Cell, Kidney Neoplasms, Urogenital Neoplasms

NCT00334282 2016-02-05

Safety and Efficacy of GW786034 (Pazopanib) In Metastatic Renal Cell Carcinoma

435 enrolled 19 charts

Carcinoma, Renal Cell, Neoplasm Metastasis

NCT01223027 2015-12-07

Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma

564 enrolled 19 charts

Carcinoma, Renal Cell

NCT00492986 2014-12-30

An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients With Advanced Renal Cell Carcinoma

1,150 enrolled

Carcinoma, Renal Cell, Neoplasms

NCT00111020 2014-08-06

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

2,567 enrolled

Carcinoma, Renal Cell

NCT00586105 2014-04-16

Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)

39 enrolled 21 charts